Strota/ Newsroom/ 2026-07-11

MANKIND (Mankind Pharma Ltd.): Acquisition / M&A

Strota Newsroom · session of 2026-07-11 · 11 Jul 13:28 · MANKIND stock page →

Mankind Pharma Limited has informed the Exchange about Acquisition Historically, acquisition / m&a events have moved MANKIND-type stocks in the bullish direction 48.9% of the next sessions (n=141).

Mankind Pharma Ltd. informed the National Stock Exchange on 11 July 2026 that it has completed an acquisition, according to the exchange filing. The company did not disclose deal terms in the headline announcement.

Strota's historical base rate for acquisition announcements shows mixed outcomes: across 141 comparable events, the win rate stands at 48.9% with a net edge of 0.213 percentage points over the subsequent period. This means events like this have historically produced slightly positive but inconsistent returns, with roughly half of cases underperforming.

The stock closed at ₹2,525.1 on 10 July, down 0.36% from the previous session, while the Nifty rose 1.02%. Mankind Pharma trades 7.05% below its 52-week high of ₹2,716.5 and 32.22% above its 52-week low. Relative volume at 1.26 indicates modestly elevated turnover. The RSI of 58.1 sits in neutral territory, and the price holds above both its 50-day and 200-day moving averages. Valuation metrics show a price-to-earnings ratio of 54.49 and price-to-book of 6.39 on a market capitalisation of ₹1,04,286 crore. Futures and options data flags a "Short Buildup" classification, with open interest rising 5.09% alongside a 0.22% price decline.

The filing confirms an acquisition has occurred but does not establish the target, purchase price, financing method, or expected financial impact. Investors would need the full disclosure to assess dilution risk, integration costs, or revenue accretion.

The catalyst

Mankind Pharma Limited has informed the Exchange about Acquisition (filing · NSE)

What the data shows after this event

Across Strota's backtest of past filings, Acquisition / M&A shows no reliable next-session edge — the move went bullish in about 48.9% of next sessions (net 0.213% after drift and cost, n=141). A base rate, not a forecast for this stock.

MANKIND right now

trading -0.36% on the day; F&O shows Short Buildup (OI 5.09% ); P/E 54.49; RSI 58.1. Full MANKIND analysis →

Sources

Mankind Pharma Limited has informed the Exchange about Acquisition — NSE
Mankind Pharma Shares In Focus As InCred Initiates Coverage, Eyes 11% Upside — Check Target Price — NDTV Profit
Mankind Pharma Ltd. Actuals & Estimates (NSE:MANKIND) — TradingView
MANKIND Forecast — Price Target — Prediction for 2027 — TradingView
Five Stocks To Buy: Eternal, Trent, Eicher Motors And More | June 22, 2026 — NDTV Profit

Keep digging

MANKIND — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
Newsroom: the other stocks in play this session.

How this article was made: Strota assembled the exchange data above (prices, F&O open interest, bulk/block deals, SEBI PIT filings, indicator readings and public headlines) and an AI model wrote the narrative strictly from that evidence — it is not permitted to add outside facts or numbers. Every figure comes from the underlying exchange/public data.